Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Nonfatal CV outcomes similar between allopurinol and febuxostat treatment for gout

24 Jun 2019

In the treatment of gout, the risk of nonfatal cardiovascular (CV) events, including myocardial infarction (MI) and stroke, does not significantly differ between allopurinol and febuxostat, a study has shown.

The study population comprised gout patients from Korea: 39,640 allopurinol initiators and 9,910 propensity score-matched febuxostat initiators. The mean age was 59.1 years, and 78.4 percent were male.

A composite CV event of MI, stroke/transient ischaemic attack or coronary revascularization was the primary outcome. Its incidence rate was 1.89 per 100 person-years in the allopurinol group vs 1.84 per 100 person-years in the febuxostat group (hazard ratio [HR], 1.09, 95 percent CI, 0.90–1.32).

Secondary outcomes included the individual components of the primary outcome and all-cause mortality. There was no significant difference observed between the two treatment groups (HR for all-cause mortality, 0.96, 0.79–1.16).

Results were similar in subgroup analyses limited to patients at high CV risk and to equipotent-dose initiators (ie, allopurinol ≥300 mg/day vs febuxostat ≥40 mg/day).

The findings replicate the recent US Medicare population study, researchers said. However, the current study represents a much younger population of Asians with a much lower prevalence of underlying CV conditions and risk factors than Medicare patients. [Circulation 2019;138:1116-1126]

Therefore, the present data contribute to the generalizability of the comparable CV risk between allopurinol and febuxostat, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).